EUVIMEDEUVIMED entdecken
Open Access

Thiazole‐Derived Dual EGFR/CDK‐2 Inhibitors: Rational Design, Synthesis, In Vitro Anticancer Evaluation, Mechanistic Profiling, and Computational Binding Analysis

Rowida Nasr, Mohamed S Nafie iD, Hesham Haffez iD, Mohamed Ahmed A Moustafa, Mohamed M El-Kerdawy, Ahmed R Ali iD

Archiv der Pharmazie · 2026-07 · 359 (7)

DOI: 10.1002/ardp.70308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 17.07.2026. Verfasst von Rowida Nasr und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Thiazoles, Antineoplastic Agents, Drug Design, Cyclin-Dependent Kinase 2. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New series of thiazole analogues were designed, synthesized, and tested for their potential anticancer activity. All the synthesized compounds were biologically tested against HCT‐116 and MCF‐7 cell lines. Compounds 14d , 14h , and 14i were determined to be the most active members in this series against HCT‐116 cancer cell lines with a considerable safety profile. The three lead compounds were further investigated for their inhibitory activities against EGFR and CDK‐2. Compound 14i exhibited the most potent inhibition, with IC 50 values of 0.056 and 0.215 µM against EGFR and CDK‐2, respectively, suggesting a possible association between kinase inhibition and the observed cellular activity. Compounds 14d , 14h , and 14i induced early apoptosis (14.40%–18.09%) and G 2 /M arrest (51.55%–66.15% population) in HCT‐116 cells, with minimal necrosis. Additionally, the screened compounds upregulated pro‐apoptotic factors (Bax, cytochrome c, and cleaved caspase‐3), while downregulating pro‐survival/anti‐apoptotic markers (p‐AKT1, Bcl‐2) and the angiogenic factor VEGF, offering preliminary insight into the potential mechanism of action. EGFR and CDK‐2 were among the most prominent genes identified in the network pharmacology analysis of the tested compounds. Molecular docking and molecular dynamics simulations suggested favorable binding modes of compound 14i within the active sites of EGFR and CDK‐2, with stable interaction patterns observed during the simulation period. Furthermore, compounds 14d , 14h , and 14i showed encouraging in silico ADMET and drug‐likeness profiles. Overall, these findings highlight the thiazole series as promising lead compounds with potential dual inhibitory activity, warranting further optimization and mechanistic validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolesAntineoplastic AgentsDrug DesignCyclin-Dependent Kinase 2Protein Kinase InhibitorsHumansErbB ReceptorsStructure-Activity RelationshipMolecular Docking SimulationApoptosisDrug Screening Assays, AntitumorMolecular StructureCell ProliferationDose-Response Relationship, DrugHCT116 CellsMCF-7 Cells

Stichwörter der Autor:innen

anticancerapoptosiscell cycle arrestdual EGFR/CDK‐2 inhibitionmolecular dockingmolecular dynamics simulationnetwork pharmacologysynthesisthiazole

Substanzen

ThiazolesErbB ReceptorsAntineoplastic AgentsCyclin-Dependent Kinase 2Protein Kinase InhibitorsEGFR protein, humanCDK2 protein, human

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, UAE.
  • Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt.
  • Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Capital University (formerly Helwan University), Cairo, Egypt.
  • Center of Scientific Excellence "Helwan Structural Biology Research, (HSBR)", Capital University (formerly Helwan University), Cairo, Egypt.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.

ORCID-Profile: Mohamed S Nafie, Hesham Haffez, Ahmed R Ali

Zitieren

APA

Nasr, R., Nafie, M. S., Haffez, H., Moustafa, M. A. A., El-Kerdawy, M. M., & Ali, A. R. (2026). Thiazole‐Derived Dual EGFR/CDK‐2 Inhibitors: Rational Design, Synthesis, In Vitro Anticancer Evaluation, Mechanistic Profiling, and Computational Binding Analysis. Archiv der Pharmazie, 359(7). https://doi.org/10.1002/ardp.70308

Vancouver

Nasr R, Nafie MS, Haffez H, Moustafa MAA, El-Kerdawy MM, Ali AR. Thiazole‐Derived Dual EGFR/CDK‐2 Inhibitors: Rational Design, Synthesis, In Vitro Anticancer Evaluation, Mechanistic Profiling, and Computational Binding Analysis. Archiv der Pharmazie. 2026;359(7). doi:10.1002/ardp.70308

BibTeX
@article{Nasr2026,
  author = {Nasr, Rowida and Nafie, Mohamed S and Haffez, Hesham and Moustafa, Mohamed Ahmed A and El-Kerdawy, Mohamed M and Ali, Ahmed R},
  title = {Thiazole‐Derived Dual EGFR/CDK‐2 Inhibitors: Rational Design, Synthesis, In Vitro Anticancer Evaluation, Mechanistic Profiling, and Computational Binding Analysis},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {7},
  doi = {10.1002/ardp.70308}
}
Kostenlos starten →